Solifenacin at 3 Years: A Review of Efficacy and Safety

Pelman, Richard S.; Capo, James P.; Forero-Schwanhaeuser, Sergio

doi:10.3810/pgm.2008.07.1795

Cited by 16 publications

(10 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical research has shown that the use of anticholinergic drugs for the treatment of overactive bladder symptoms reduces urinary urgency by about 60%, reduces micturition frequency by about 25%, and reduces urinary incontinence by about 80%. 26 – 28 These data support the notion that dry OAB patients have symptoms that would be better managed with therapy directed towards interstitial cystitis/painful bladder syndrome. It has recently been demonstrated in a randomized 2-year study of 82 patients with OAB that 0.2% chondroitin sulfate installation provided much better response than Tolterodine provided (73% vs 43% at 12 months and 56% vs 14% after 24 months) after 12 months of therapy.…”

Section: Discussionsupporting

confidence: 62%

The Overlap of Interstitial Cystitis/Painful Bladder Syndrome and Overactive Bladder

Chung¹,

Butrick

Chung³

2010

JSLS

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 62%

The Overlap of Interstitial Cystitis/Painful Bladder Syndrome and Overactive Bladder

Chung¹,

Butrick

Chung³

2010

JSLS

View full text Add to dashboard Cite

show abstract

“…Solifenacin (Vesicare ® , SOL), a member of isoquinolines (Figure 1), has been viewed as an oral anticholinergic (i.e., a competitive muscarinic [M 1 and M 3 ] receptor antagonist) and antispasmodic agent used to treat the symptoms of overactive bladder, neurogenic detrusor overactivity, or urinary incontinence [1][2][3][4][5][6][7][8]. It has been reported to be a muscarinic (M 2 and M 3 ) receptor antagonist that has anticholinergic effects such as relaxation of the detrusor muscle in urinary bladder [9].…”

Section: Introductionmentioning

confidence: 99%

The Effectiveness in Activating M-Type K+ Current Produced by Solifenacin ([(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate): Independent of Its Antimuscarinic Action

Cho

Chuang

2021

IJMS

View full text Add to dashboard Cite

Solifenacin (Vesicare®, SOL), known to be a member of isoquinolines, is a muscarinic antagonist that has anticholinergic effect, and it has been beneficial in treating urinary incontinence and neurogenic detrusor overactivity. However, the information regarding the effects of SOL on membrane ionic currents is largely uncertain, despite its clinically wide use in patients with those disorders. In this study, the whole-cell current recordings revealed that upon membrane depolarization in pituitary GH3 cells, the exposure to SOL concentration-dependently increased the amplitude of M-type K+ current (IK(M)) with effective EC50 value of 0.34 μM. The activation time constant of IK(M) was concurrently shortened in the SOL presence, hence yielding the KD value of 0.55 μM based on minimal reaction scheme. As cells were exposed to SOL, the steady-state activation curve of IK(M) was shifted along the voltage axis to the left with no change in the gating charge of the current. Upon an isosceles-triangular ramp pulse, the hysteretic area of IK(M) was increased by adding SOL. As cells were continually exposed to SOL, further application of acetylcholine (1 μM) failed to modify SOL-stimulated IK(M); however, subsequent addition of thyrotropin releasing hormone (TRH, 1 μM) was able to counteract SOL-induced increase in IK(M) amplitude. In cell-attached single-channel current recordings, bath addition of SOL led to an increase in the activity of M-type K+ (KM) channels with no change in the single channel conductance; the mean open time of the channel became lengthened. In whole-cell current-clamp recordings, the SOL application reduced the firing of action potentials (APs) in GH3 cells; however, either subsequent addition of TRH or linopirdine was able to reverse SOL-mediated decrease in AP firing. In hippocampal mHippoE-14 neurons, the IK(M) was also stimulated by adding SOL. Altogether, findings from this study disclosed for the first time the effectiveness of SOL in interacting with KM channels and hence in stimulating IK(M) in electrically excitable cells, and this noticeable action appears to be independent of its antagonistic activity on the canonical binding to muscarinic receptors expressed in GH3 or mHippoE-14 cells.

show abstract

“…This medication class targets M3 muscarinic receptors to decrease smooth muscle contraction, relieving UUI symptoms of urgency, frequency and urgency incontinence [1]. Although solifenacin decreases urgency episodes in approximately 60% of treated patients, symptoms may persist [2–4] with approximately 40% of treated patients reporting bothersome symptoms [5]. Clinicians recognize this lack of response, although the cause remains unclear and studies into the biologic basis for persistent symptoms are lacking.…”

Section: Introductionmentioning

confidence: 99%

Incontinence medication response relates to the female urinary microbiota

et al. 2015

View full text Add to dashboard Cite

Introduction Many adult women have resident urinary bacteria (urinary microbiome/microbiota). In adult women affected by urinary urgency incontinence (UUI), the etiologic and/or therapeutic role of the urinary microbiome/microbiota remains unknown. Hypothesis Microbiome/microbiota characteristics will relate to clinically relevant treatment response to oral UUI medication. Methods Adult women initiating oral medication treatment for UUI and a comparator group of unaffected women were recruited in a tertiary care health care system. All participants provided baseline clinical data and urine. Women with UUI were given 5mg solifenacin with potential dose escalation to 10mg for inadequate UUI symptoms control at 4 weeks. Additional data and urine samples were collected from women with UUI at 4 and 12 weeks. The samples were assessed by 16S rRNA gene sequencing and enhanced quantitative urine culturing. The primary outcome was treatment response as measured by the validated Patient Global Symptom Control (PGSC) questionnaire. Clinically relevant UUI symptom control was defined as a 4 or 5 score on the PGSC. Results The diversity and composition of the urinary microbiome/microbiota of women with and without UUI differed at baseline. Women with UUI had more bacteria and a more diverse microbiome/microbiota. The clinical response to solifenacin in UUI participants was related to baseline microbiome/microbiota, with responders more likely to have fewer bacteria and a less diverse community at baseline. Non-responders had a more diverse community that often included bacteria not typically found in responders. Conclusions Knowledge of an individual’s urinary microbiome/microbiota may help refine UUI treatment. Complementary tools, DNA sequencing and expanded urine culture, provide information about bacteria that appear related to UUI incontinence status and UUI treatment response in this population of adult women.

show abstract

Solifenacin at 3 Years: A Review of Efficacy and Safety

Cited by 16 publications

References 14 publications

The Overlap of Interstitial Cystitis/Painful Bladder Syndrome and Overactive Bladder

The Overlap of Interstitial Cystitis/Painful Bladder Syndrome and Overactive Bladder

The Effectiveness in Activating M-Type K+ Current Produced by Solifenacin ([(3R)-1-azabicyclo[2.2.2]octan-3-yl] (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate): Independent of Its Antimuscarinic Action

Incontinence medication response relates to the female urinary microbiota

Contact Info

Product

Resources

About